Analyzing R&D Budgets: Teva Pharmaceutical Industries Limited vs Alkermes plc

Teva vs. Alkermes: A Decade of R&D Investment Trends

__timestampAlkermes plcTeva Pharmaceutical Industries Limited
Wednesday, January 1, 201477530001488000000
Thursday, January 1, 201540190001525000000
Friday, January 1, 201623010002111000000
Sunday, January 1, 201772320001848000000
Monday, January 1, 2018688950001213000000
Tuesday, January 1, 2019528160001010000000
Wednesday, January 1, 20201946000997000000
Friday, January 1, 20211020000967000000
Saturday, January 1, 2022393842000838000000
Sunday, January 1, 2023270806000953000000
Monday, January 1, 2024245326000998000000
Loading chart...

Igniting the spark of knowledge

A Decade of R&D Investment: Teva vs. Alkermes

In the competitive landscape of pharmaceuticals, research and development (R&D) spending is a critical indicator of innovation and future growth. Over the past decade, Teva Pharmaceutical Industries Limited and Alkermes plc have demonstrated contrasting strategies in their R&D investments.

From 2014 to 2023, Teva consistently allocated a significant portion of its budget to R&D, peaking in 2016 with a 63% increase compared to 2014. However, a downward trend followed, with a 36% reduction by 2022. In contrast, Alkermes showed a more volatile pattern, with a remarkable 5,000% surge in 2022, highlighting a strategic pivot towards innovation.

These trends underscore the dynamic nature of pharmaceutical R&D, where strategic shifts can dramatically alter a company's trajectory. As the industry evolves, monitoring these investments offers valuable insights into future breakthroughs and market leadership.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025